Country Access Report
Czechia has a narrow therapeutic psilocybin framework from 1 January 2026, but routine psilocybin treatment had not yet started according to NUDZ's March 2026 statement. Real current access is led by reimbursed, supervised esketamine for defined treatment-resistant depression criteria and off-label ketamine in selected private or organisation-specific settings. Other classical psychedelics remain controlled and research-only.
Read the access level as a starting point, then check the compound notes below. The practical question is whether a patient can move through a real pathway today, or whether access still depends on a trial, exception route, private-care model, or future reimbursement decision.
Look for approved use, named specialist settings, eligibility rules, and whether care is routine or exceptional.
Separate clinical trials, special access, compassionate use, and unlicensed-medicine routes from routine medical availability.
Check who pays, where care can happen, and whether trained teams, product supply, and site governance are in place.
These notes separate what is available today from research, exceptional-access, private-care, and payment routes. When the guide has not verified a pathway, the compound stays marked as incomplete rather than treated as unavailable.
Compound Access
Czechia permits therapeutic psilocybin from 1 January 2026 only inside a narrow medical framework: qualified specialist physicians, defined mental-health indications, oral individually prepared medicine, dose limits and special supervision. NUDZ stated in March 2026 that treatment had not yet started and no waiting list was open. [1] [2]
Compound Access
MDMA remains a controlled psychotropic substance. No routine Czech medical access or reimbursement route was identified in reviewed sources; lawful use would depend on authorised research. [1]
Compound Access
Compound Access
Ketamine remains an off-label psychiatric option in Czechia. Psyon states that ketamine-assisted therapy in mental-health indications is off-label and describes partial insurer coverage for some clients, but this is organisation-level evidence rather than a national reimbursement standard. [1]
Compound Access
DMT remains controlled. No authorised routine medical access or public reimbursement route was identified; any lawful use would require approved research or another formal authorisation. [1]
Compound Access
Compound Access
Compound Access
Compound Access
Mescaline remains controlled. No authorised Czech patient-access or reimbursement route was identified outside approved research. [1]
Compound Access
2C-family substances remain a controlled-substance issue rather than a medical-access pathway. No Czech treatment or reimbursement route was identified in reviewed sources. [1]
Last updated 13 May 2026. Source links come from the medical access guide.